MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLC

Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.